Find Hydroxypropyl-Beta Cyclodextrin manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

JDMF

JDMFs Filed

0

KDMF

KDMF

0

VMF

NDC API

0

Listed Suppliers

Other Suppliers

API REF. PRICE (USD/KG)

MARKET PLACE

0

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

0

FDF Dossiers

FDF Dossiers

0

FDA Orange Book

FDA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

DIGITAL CONTENT

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Finished Drug Prices

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 107745-73-3, Hp-beta-cd, 2-hydroxypropyl-, A-cyclodextrin, 6a,6b,6c,6d,6e,6f,6g-heptakis-o-(2-hydroxypropyl)-beta-cyclodextrin, Trappsol hpb
Molecular Formula
C63H112O42
Molecular Weight
1541.5  g/mol
InChI Key
ODLHGICHYURWBS-LKONHMLTSA-N

Hydroxypropyl-Beta Cyclodextrin
Derivative of beta-cyclodextrin that is used as an excipient for steroid drugs and as a lipid chelator.
1 2D Structure

Hydroxypropyl-Beta Cyclodextrin

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
(1S,3R,5R,6S,8R,10R,11S,13R,15R,16S,18R,20R,21S,23R,25R,26S,28R,30R,31S,33R,35R,36R,37R,38R,39R,40R,41R,42R,43R,44R,45R,46R,47R,48R,49R)-5,10,15,20,25,30,35-heptakis(2-hydroxypropoxymethyl)-2,4,7,9,12,14,17,19,22,24,27,29,32,34-tetradecaoxaoctacyclo[31.2.2.23,6.28,11.213,16.218,21.223,26.228,31]nonatetracontane-36,37,38,39,40,41,42,43,44,45,46,47,48,49-tetradecol
2.1.2 InChI
InChI=1S/C63H112O42/c1-22(64)8-85-15-29-50-36(71)43(78)57(92-29)100-51-30(16-86-9-23(2)65)94-59(45(80)38(51)73)102-53-32(18-88-11-25(4)67)96-61(47(82)40(53)75)104-55-34(20-90-13-27(6)69)98-63(49(84)42(55)77)105-56-35(21-91-14-28(7)70)97-62(48(83)41(56)76)103-54-33(19-89-12-26(5)68)95-60(46(81)39(54)74)101-52-31(17-87-10-24(3)66)93-58(99-50)44(79)37(52)72/h22-84H,8-21H2,1-7H3/t22?,23?,24?,25?,26?,27?,28?,29-,30-,31-,32-,33-,34-,35-,36-,37-,38-,39-,40-,41-,42-,43-,44-,45-,46-,47-,48-,49-,50-,51-,52-,53-,54-,55-,56-,57-,58-,59-,60-,61-,62-,63-/m1/s1
2.1.3 InChI Key
ODLHGICHYURWBS-LKONHMLTSA-N
2.1.4 Canonical SMILES
CC(COCC1C2C(C(C(O1)OC3C(OC(C(C3O)O)OC4C(OC(C(C4O)O)OC5C(OC(C(C5O)O)OC6C(OC(C(C6O)O)OC7C(OC(C(C7O)O)OC8C(OC(O2)C(C8O)O)COCC(C)O)COCC(C)O)COCC(C)O)COCC(C)O)COCC(C)O)COCC(C)O)O)O)O
2.1.5 Isomeric SMILES
CC(COC[C@@H]1[C@@H]2[C@@H]([C@H]([C@H](O1)O[C@@H]3[C@H](O[C@@H]([C@@H]([C@H]3O)O)O[C@@H]4[C@H](O[C@@H]([C@@H]([C@H]4O)O)O[C@@H]5[C@H](O[C@@H]([C@@H]([C@H]5O)O)O[C@@H]6[C@H](O[C@@H]([C@@H]([C@H]6O)O)O[C@@H]7[C@H](O[C@@H]([C@@H]([C@H]7O)O)O[C@@H]8[C@H](O[C@H](O2)[C@@H]([C@H]8O)O)COCC(C)O)COCC(C)O)COCC(C)O)COCC(C)O)COCC(C)O)COCC(C)O)O)O)O
2.2 Synonyms
2.2.1 MeSH Synonyms

1. 2 Hydroxypropyl Beta Cyclodextrin

2. 2 Hydroxypropyl-beta-cyclodextrin

3. 2-hydroxypropyl-beta-cyclodextrin

4. Beta Hydroxypropylcyclodextrin

5. Beta-hydroxypropylcyclodextrin

6. Betadex, Hydroxypropyl

7. Hp-beta-cd

8. Hpbetacd

9. Hydroxypropyl Beta Cyclodextrin

10. Hydroxypropyl Betadex

11. Hydroxypropyl-beta-cyclodextrin

2.2.2 Depositor-Supplied Synonyms

1. 107745-73-3

2. Hp-beta-cd

3. 2-hydroxypropyl-

4. A-cyclodextrin

5. 6a,6b,6c,6d,6e,6f,6g-heptakis-o-(2-hydroxypropyl)-beta-cyclodextrin

6. Trappsol Hpb

7. Hydroxypropylbetadex

8. Thpb

9. Hydroxypropyl-beta-cyclodextri

10. Hydroxypropyl-beta Cyclodextrin

11. Chembl577294

12. Dtxsid401017375

13. .beta.-cyclodextrin, 6a,6b,6c,6d,6e,6f,6g-heptakis-o-(2-hydroxypropyl)-

14. 6a,6b,6c,6d,6e,6f,6g-heptakis-o-(2-hydroxypropyl)-beta-cyclodextrinr

2.3 Create Date
2007-02-09
3 Chemical and Physical Properties
Molecular Weight 1541.5 g/mol
Molecular Formula C63H112O42
XLogP3-13
Hydrogen Bond Donor Count21
Hydrogen Bond Acceptor Count42
Rotatable Bond Count28
Exact Mass1540.6628176 g/mol
Monoisotopic Mass1540.6628176 g/mol
Topological Polar Surface Area619 Ų
Heavy Atom Count105
Formal Charge0
Complexity2010
Isotope Atom Count0
Defined Atom Stereocenter Count35
Undefined Atom Stereocenter Count7
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Pharmacology and Biochemistry
4.1 MeSH Pharmacological Classification

Excipients

Usually inert substances added to a prescription in order to provide suitable consistency to the dosage form. These include binders, matrix, base or diluent in pills, tablets, creams, salves, etc. (See all compounds classified as Excipients.)


Drugs in Development

read-more
read-more

Details:

The combined company will focus on the development of Trappsol Cyclo (hydroxypropyl-beta cyclodextrin) for the treatment of Niemann-Pick Disease Type C1.


Lead Product(s): Hydroxypropyl-Beta Cyclodextrin

Therapeutic Area: Rare Diseases and Disorders Brand Name: Trappsol Cyclo

Study Phase: Phase IIIProduct Type: Small molecule

Sponsor: Cyclo Therapeutics

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Merger August 22, 2024

blank

01

Medlab Asia & Asia Health
Not Confirmed
Medlab Asia & Asia Health
Not Confirmed

Details : The combined company will focus on the development of Trappsol Cyclo (hydroxypropyl-beta cyclodextrin) for the treatment of Niemann-Pick Disease Type C1.

Brand Name : Trappsol Cyclo

Molecule Type : Small molecule

Upfront Cash : Undisclosed

August 22, 2024

blank

Details:

Trappsol Cyclo (hydroxypropyl betacyclodextrin) is being evaluated for the treatment of systemic and neurological symptoms of Niemann-Pick Disease Type C1.


Lead Product(s): Hydroxypropyl-Beta Cyclodextrin

Therapeutic Area: Rare Diseases and Disorders Brand Name: Trappsol Cyclo

Study Phase: Phase IIIProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 30, 2024

blank

02

Medlab Asia & Asia Health
Not Confirmed
Medlab Asia & Asia Health
Not Confirmed

Details : Trappsol Cyclo (hydroxypropyl betacyclodextrin) is being evaluated for the treatment of systemic and neurological symptoms of Niemann-Pick Disease Type C1.

Brand Name : Trappsol Cyclo

Molecule Type : Small molecule

Upfront Cash : Not Applicable

May 30, 2024

blank

Details:

VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is being developed to mediate removal of excess cholesterol that damages the kidneys’ filtration system in patients with Diabetic Kidney Disease.


Lead Product(s): Hydroxypropyl-Beta Cyclodextrin

Therapeutic Area: Nephrology Brand Name: VAR 200

Study Phase: Phase IProduct Type: Large molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 18, 2024

blank

03

Medlab Asia & Asia Health
Not Confirmed
Medlab Asia & Asia Health
Not Confirmed

Details : VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is being developed to mediate removal of excess cholesterol that damages the kidneys’ filtration system in patients with Diabetic Kidney Disease.

Brand Name : VAR 200

Molecule Type : Large molecule

Upfront Cash : Not Applicable

March 18, 2024

blank

Details:

The combined company will focus on advancing Cyclo Therapeutics’ pivotal Phase 3 global study evaluating Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug designated product in the United States and Europe, for Niemann-Pick Disease Type C1 (NPC1).


Lead Product(s): Hydroxypropyl-Beta Cyclodextrin

Therapeutic Area: Rare Diseases and Disorders Brand Name: Trappsol Cyclo

Study Phase: Phase IIIProduct Type: Large molecule

Sponsor: Cyclo Therapeutics

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Merger December 27, 2023

blank

04

Medlab Asia & Asia Health
Not Confirmed
Medlab Asia & Asia Health
Not Confirmed

Details : The combined company will focus on advancing Cyclo Therapeutics’ pivotal Phase 3 global study evaluating Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug designated product in the United States and Europe, for Niemann-Pick Disease Type ...

Brand Name : Trappsol Cyclo

Molecule Type : Large molecule

Upfront Cash : Undisclosed

December 27, 2023

blank

Details:

Trappsol Cyclo is a proprietary formulation of hydroxypropyl beta cyclodextrin being developed in phase 3 clinical trials for the potential treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease.


Lead Product(s): Hydroxypropyl-Beta Cyclodextrin

Therapeutic Area: Rare Diseases and Disorders Brand Name: Trappsol Cyclo

Study Phase: Phase IIIProduct Type: Large molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable December 18, 2023

blank

05

Medlab Asia & Asia Health
Not Confirmed
Medlab Asia & Asia Health
Not Confirmed

Details : Trappsol Cyclo is a proprietary formulation of hydroxypropyl beta cyclodextrin being developed in phase 3 clinical trials for the potential treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease.

Brand Name : Trappsol Cyclo

Molecule Type : Large molecule

Upfront Cash : Not Applicable

December 18, 2023

blank

Details:

VAR 200 (2-hydroxypropyl-beta-cyclodextrin, 2HPβCD) is a phase 2a-ready drug in development which has potential to treat multiple kidney diseases, including diabetic kidney disease, rare kidney diseases, FSGS (focal segmental glomerulosclerosis) and Alport syndrome.


Lead Product(s): Hydroxypropyl-Beta Cyclodextrin

Therapeutic Area: Nephrology Brand Name: VAR 200

Study Phase: Phase IProduct Type: Large molecule

Sponsor: George Clinical

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable December 14, 2023

blank

06

Medlab Asia & Asia Health
Not Confirmed
Medlab Asia & Asia Health
Not Confirmed

Details : VAR 200 (2-hydroxypropyl-beta-cyclodextrin, 2HPβCD) is a phase 2a-ready drug in development which has potential to treat multiple kidney diseases, including diabetic kidney disease, rare kidney diseases, FSGS (focal segmental glomerulosclerosis) and Alp...

Brand Name : VAR 200

Molecule Type : Large molecule

Upfront Cash : Not Applicable

December 14, 2023

blank

Details:

The combined company will focus on advancing Cyclo Therapeutics’ pivotal Phase 3 global study evaluating Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug designated product in the United States and Europe, for Niemann-Pick Disease Type C1 (NPC1).


Lead Product(s): Hydroxypropyl-Beta Cyclodextrin

Therapeutic Area: Rare Diseases and Disorders Brand Name: Trappsol Cyclo

Study Phase: Phase IIIProduct Type: Large molecule

Sponsor: Cyclo Therapeutics

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Merger September 21, 2023

blank

07

Medlab Asia & Asia Health
Not Confirmed
Medlab Asia & Asia Health
Not Confirmed

Details : The combined company will focus on advancing Cyclo Therapeutics’ pivotal Phase 3 global study evaluating Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug designated product in the United States and Europe, for Niemann-Pick Disease Type ...

Brand Name : Trappsol Cyclo

Molecule Type : Large molecule

Upfront Cash : Undisclosed

September 21, 2023

blank

Details:

Cyclo Therapeutics intends to use the proceeds to support of its Trappsol Cyclo, a proprietary formulation of hydroxypropyl beta cyclodextrin being developed in clinical trials for the potential treatment of Niemann-Pick Disease Type C1, a rare, fatal and Alzheimer’s disease.


Lead Product(s): Hydroxypropyl-Beta Cyclodextrin

Therapeutic Area: Rare Diseases and Disorders Brand Name: Trappsol Cyclo

Study Phase: Phase IIIProduct Type: Large molecule

Sponsor: Rafael Holdings

Deal Size: $5.0 million Upfront Cash: Undisclosed

Deal Type: Private Placement August 02, 2023

blank

08

Medlab Asia & Asia Health
Not Confirmed
Medlab Asia & Asia Health
Not Confirmed

Details : Cyclo Therapeutics intends to use the proceeds to support of its Trappsol Cyclo, a proprietary formulation of hydroxypropyl beta cyclodextrin being developed in clinical trials for the potential treatment of Niemann-Pick Disease Type C1, a rare, fatal an...

Brand Name : Trappsol Cyclo

Molecule Type : Large molecule

Upfront Cash : Undisclosed

August 02, 2023

blank

Details:

Cyclo Therapeutics intends to use the proceeds for the support of its Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug designated product in the United States and Europe, under clinical trial for Niemann-Pick Disease Type C, a rare and fatal genetic disease.


Lead Product(s): Hydroxypropyl-Beta Cyclodextrin

Therapeutic Area: Rare Diseases and Disorders Brand Name: Trappsol Cyclo

Study Phase: Phase IIIProduct Type: Large molecule

Sponsor: Rafael Holdings

Deal Size: $5.0 million Upfront Cash: Undisclosed

Deal Type: Private Placement June 05, 2023

blank

09

Medlab Asia & Asia Health
Not Confirmed
Medlab Asia & Asia Health
Not Confirmed

Details : Cyclo Therapeutics intends to use the proceeds for the support of its Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug designated product in the United States and Europe, under clinical trial for Niemann-Pick Disease Type C, a rare and fa...

Brand Name : Trappsol Cyclo

Molecule Type : Large molecule

Upfront Cash : Undisclosed

June 05, 2023

blank

Details:

Trappsol® Cyclo™ (hydroxypropyl beta cyclodextrin), effectively manages the transportation of cholesterol accumulated out of the cells by taking the place of the defective NPC1 protein. It is currently being evaluated for Early Alzheimer’s Disease and NPC1.


Lead Product(s): Hydroxypropyl-Beta Cyclodextrin

Therapeutic Area: Rare Diseases and Disorders Brand Name: Trappsol Cyclo

Study Phase: Phase IIIProduct Type: Large molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 11, 2023

blank

10

Medlab Asia & Asia Health
Not Confirmed
Medlab Asia & Asia Health
Not Confirmed

Details : Trappsol® Cyclo™ (hydroxypropyl beta cyclodextrin), effectively manages the transportation of cholesterol accumulated out of the cells by taking the place of the defective NPC1 protein. It is currently being evaluated for Early Alzheimer’s Disease a...

Brand Name : Trappsol Cyclo

Molecule Type : Large molecule

Upfront Cash : Not Applicable

January 11, 2023

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more

NEWS #PharmaBuzz

read-more
read-more

Market Place

Do you need sourcing support? Ask us

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty